Agilent Technologies Inc. (A)

$137.49

-1.71

(-1.23%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Agilent Technologies Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.68B → 1.65B (in $), with an average decrease of 1.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 475.0M → 348.0M (in $), with an average decrease of 26.7% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 25.6% return, outperforming this stock by 20.1%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 3.7% return, outperforming this stock by 3.1%

Performance

  • $136.29
    $139.77
    $137.49
    downward going graph

    0.88%

    Downside

    Day's Volatility :2.49%

    Upside

    1.63%

    downward going graph
  • $96.48
    $151.33
    $137.49
    downward going graph

    29.83%

    Downside

    52 Weeks Volatility :36.25%

    Upside

    9.15%

    downward going graph

Returns

PeriodAgilent Technologies Inc.Sector (Health Care)S&P500
3 Months
5.86%
1.7%
3.6%
6 Months
32.97%
11.3%
21.1%
1 Year
5.46%
5.4%
24.6%
3 Years
0.11%
13.9%
21.3%

Highlights

Market Capitalization
40.8B
Book Value
$21.12
Dividend Share
0.911
Dividend Yield
0.68%
Earnings Per Share (EPS)
4.18
PE Ratio
33.3
PEG Ratio
2.7
Wall Street Target Price
149.36
Profit Margin
18.35%
Operating Margin TTM
24.07%
Return On Assets TTM
7.85%
Return On Equity TTM
20.95%
Revenue TTM
6.7B
Revenue Per Share TTM
22.97
Quarterly Revenue Growth YOY
-5.6000000000000005%
Gross Profit TTM
3.5B
EBITDA
1.6B
Diluted Eps TTM
4.18
Quarterly Earnings Growth YOY
-0.01
EPS Estimate Current Year
5.5
EPS Estimate Next Year
6.08
EPS Estimate Current Quarter
1.22
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    60%Buy
    36%Hold
    4%Sell
Based on 25 Wall street analysts offering stock ratings for Agilent Technologies Inc.(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
18
Hold
9
9
7
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 8.63%

Current $137.49
Target $149.36

Company Financials

FY18Y/Y Change
Revenue
4.9B
↑ 9.88%
Net Income
316.0M
↓ 53.8%
Net Profit Margin
6.43%
↓ 8.87%
FY19Y/Y Change
Revenue
5.2B
↑ 5.07%
Net Income
1.1B
↑ 238.92%
Net Profit Margin
20.74%
↑ 14.31%
FY20Y/Y Change
Revenue
5.3B
↑ 3.41%
Net Income
719.0M
↓ 32.87%
Net Profit Margin
13.47%
↓ 7.27%
FY21Y/Y Change
Revenue
6.3B
↑ 18.36%
Net Income
1.2B
↑ 68.29%
Net Profit Margin
19.15%
↑ 5.68%
FY22Y/Y Change
Revenue
6.8B
↑ 8.37%
Net Income
1.3B
↑ 3.64%
Net Profit Margin
18.31%
↓ 0.84%
FY23Y/Y Change
Revenue
6.8B
↓ 0.22%
Net Income
1.2B
↓ 1.12%
Net Profit Margin
18.15%
↓ 0.16%
Q4 FY22Q/Q Change
Revenue
1.8B
↑ 7.63%
Net Income
368.0M
↑ 11.85%
Net Profit Margin
19.9%
↑ 0.75%
Q1 FY23Q/Q Change
Revenue
1.8B
↓ 5.03%
Net Income
352.0M
↓ 4.35%
Net Profit Margin
20.05%
↑ 0.15%
Q2 FY23Q/Q Change
Revenue
1.7B
↓ 2.22%
Net Income
302.0M
↓ 14.2%
Net Profit Margin
17.59%
↓ 2.46%
Q3 FY23Q/Q Change
Revenue
1.7B
↓ 2.62%
Net Income
111.0M
↓ 63.25%
Net Profit Margin
6.64%
↓ 10.95%
Q4 FY23Q/Q Change
Revenue
1.7B
↑ 0.96%
Net Income
475.0M
↑ 327.93%
Net Profit Margin
28.14%
↑ 21.5%
Q1 FY24Q/Q Change
Revenue
1.7B
↓ 1.78%
Net Income
348.0M
↓ 26.74%
Net Profit Margin
20.99%
↓ 7.15%
FY18Y/Y Change
Total Assets
8.5B
↑ 1.33%
Total Liabilities
4.0B
↑ 10.31%
FY19Y/Y Change
Total Assets
9.5B
↑ 10.67%
Total Liabilities
4.7B
↑ 18.49%
FY20Y/Y Change
Total Assets
9.6B
↑ 1.85%
Total Liabilities
4.8B
↑ 1.06%
FY21Y/Y Change
Total Assets
10.7B
↑ 11.2%
Total Liabilities
5.3B
↑ 11.82%
FY22Y/Y Change
Total Assets
10.5B
↓ 1.77%
Total Liabilities
5.2B
↓ 1.67%
FY23Y/Y Change
Total Assets
10.8B
↑ 2.35%
Total Liabilities
4.9B
↓ 5.91%
Q4 FY22Q/Q Change
Total Assets
10.5B
↑ 0.31%
Total Liabilities
5.2B
↓ 3.08%
Q1 FY23Q/Q Change
Total Assets
10.9B
↑ 3.83%
Total Liabilities
5.3B
↑ 1.59%
Q2 FY23Q/Q Change
Total Assets
10.8B
↓ 1.16%
Total Liabilities
5.0B
↓ 5.63%
Q3 FY23Q/Q Change
Total Assets
10.7B
↓ 1.08%
Total Liabilities
5.1B
↑ 2.12%
Q4 FY23Q/Q Change
Total Assets
10.8B
↑ 0.82%
Total Liabilities
4.9B
↓ 3.89%
Q1 FY24Q/Q Change
Total Assets
10.9B
↑ 1.72%
Total Liabilities
4.8B
↓ 3.21%
FY18Y/Y Change
Operating Cash Flow
1.1B
↑ 22.27%
Investing Cash Flow
-704.0M
↑ 130.82%
Financing Cash Flow
-797.0M
↑ 294.55%
FY19Y/Y Change
Operating Cash Flow
1.0B
↓ 6.07%
Investing Cash Flow
-1.6B
↑ 125.85%
Financing Cash Flow
-299.0M
↓ 62.48%
FY20Y/Y Change
Operating Cash Flow
921.0M
↓ 9.79%
Investing Cash Flow
-147.0M
↓ 90.75%
Financing Cash Flow
-717.0M
↑ 139.8%
FY21Y/Y Change
Operating Cash Flow
1.5B
↑ 61.24%
Investing Cash Flow
-749.0M
↑ 409.52%
Financing Cash Flow
-696.0M
↓ 2.93%
FY22Y/Y Change
Operating Cash Flow
1.3B
↓ 11.65%
Investing Cash Flow
-338.0M
↓ 54.87%
Financing Cash Flow
-1.4B
↑ 97.13%
FY23Y/Y Change
Operating Cash Flow
1.8B
↑ 35.06%
Investing Cash Flow
-310.0M
↓ 8.28%
Financing Cash Flow
-930.0M
↓ 32.22%
Q4 FY22Q/Q Change
Operating Cash Flow
448.0M
↑ 37.42%
Investing Cash Flow
-110.0M
↑ 50.68%
Financing Cash Flow
-341.0M
↓ 5.8%
Q1 FY23Q/Q Change
Operating Cash Flow
296.0M
↓ 33.93%
Investing Cash Flow
-104.0M
↓ 5.45%
Financing Cash Flow
-17.0M
↓ 95.01%
Q2 FY23Q/Q Change
Operating Cash Flow
398.0M
↑ 34.46%
Investing Cash Flow
-77.0M
↓ 25.96%
Financing Cash Flow
-390.0M
↑ 2194.12%
Q3 FY23Q/Q Change
Operating Cash Flow
562.0M
↑ 41.21%
Investing Cash Flow
-270.0M
↑ 250.65%
Financing Cash Flow
-322.0M
↓ 17.44%
Q4 FY23Q/Q Change
Operating Cash Flow
516.0M
↓ 8.19%
Investing Cash Flow
-40.0M
↓ 85.19%
Financing Cash Flow
-201.0M
↓ 37.58%

Technicals Summary

Sell

Neutral

Buy

Agilent Technologies Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Agilent Technologies Inc.
Agilent Technologies Inc.
-5.54%
32.97%
5.46%
0.11%
79.21%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.69%
19.77%
2.28%
-11.49%
117.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
0.67%
33.29%
5.29%
16.87%
114.21%
Danaher Corp.
Danaher Corp.
1.05%
29.98%
7.94%
-2.98%
92.05%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-3.23%
32.9%
25.63%
3.18%
75.33%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Agilent Technologies Inc.
Agilent Technologies Inc.
33.3
33.3
2.7
5.5
0.21
0.08
0.01
21.12
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.04
49.04
4.75
11.13
0.81
0.23
NA
17.88
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.17
37.17
2.81
21.53
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
46.53
46.53
3.13
7.15
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.69
32.69
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$40.8B
79.21%
33.3
18.35%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.0B
117.09%
49.04
23.08%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.3B
114.21%
37.17
13.99%
Danaher Corp.
Danaher Corp.
Buy
$187.5B
92.05%
46.53
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.4B
75.33%
32.69
9.06%

Institutional Holdings

  • BlackRock Inc

    9.30%

  • Vanguard Group Inc

    8.63%

  • Massachusetts Financial Services Company

    4.52%

  • State Street Corporation

    4.31%

  • T. Rowe Price Investment Management,Inc.

    3.47%

  • Wellington Management Company LLP

    3.37%

Corporate Announcements

  • Agilent Technologies Inc. Dividends September,2024

    In the quarter ending September,2024. Agilent Technologies Inc. has declared dividend of $0.24

    Read More

Company Information

analytical scientists and clinical researchers worldwide rely on agilent to help fulfill their most complex laboratory demands. our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, agilent provides laboratory solutions to meet their full spectrum of needs. we work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. customers trust agilent for solutions that enable insights...for a better world.

Organization
Agilent Technologies Inc.
Employees
17700
CEO
Mr. Michael R. McMullen
Industry
Health Technology

Discover More

FAQs